Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals

Documenti analoghi

• Statin Drug‐Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources
  di: James Mease, et al.
  Pubblicazione: (2024)
• Drug Administration via Enteral Feeding Tubes: A Landscape Analysis of Information in Drug Product Labeling
  di: Sherbet Samuels, et al.
  Pubblicazione: (2026)
• Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities
  di: Anuradha Ramamoorthy, et al.
  Pubblicazione: (2025)
• Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists
  di: Mariam A. Ahmed, et al.
  Pubblicazione: (2025)
• Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023
  di: Sarah Ridge, et al.
  Pubblicazione: (2024)